drug market access, Health Technology Assessment, HTA, Leela Barham, market access
0 Comment
Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
drug market access, Drug pricing, NICE, pharma market access, Pharmaceutical Price Regulation Scheme, PPRS, UK drug market
0 Comment
Should there be a different review of NICE as part of a successor PPRS?
cancer, cancer drug, drug market access, drug prices, Oncology
0 Comment
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Deep Dive, drug market access, HTA, market access, patient advocacy groups
0 Comment
Eric Low shares his views on why hurdles remain to new drug access.
biosimilars, drug market access, Drug regulation, market access, regulatory pathway
0 Comment
Though they can reduce the costs of health care, biosimilars still face challenges to access.
drug market access, Leela Barham, market access, medicines assessment, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
drug market access, Health Technology Assessment, HTA, HTA impact, market access
0 Comment
Examining the true impact of a positive health technology assessment (HTA).
data management, Deep Dive, drug market access, market access, Partnerships, stakeholder needs
0 Comment
The steps required for successful market access.
big data, data management, Deep Dive, drug market access, market access, pricing strategy
0 Comment
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
